

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Mark Ashby

SERIAL NO.:

10/007,204

FILING DATE:

11/8/01

TITLE:

SYSTEM AND METHOD FOR DELIVERING HEMOSTASIS

PROMOTING MATERIAL TO A BLOOD VESSEL PUNCTURE

SITE BY FLUID PRESSURE

EXAMINER:

Kennedy, Sharon E

ART UNIT:

3762

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as First Class

PECENTER 2004 P.O. Box 1450, Mail in an envelope addressed to: Commissioner for Patents Alexandria, VA 22313-1450,

on the date printed below:

Date: April 252004

Name:

Ruth Rodriquez

COMMISSIONER FOR PATENTS P.O. Box 1450, ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Each item of information listed in the attached FORM PTO-1449, for which a copy of each is attached (unless the blanket waiver referred to below applies), may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR §§ 1.56, 1.97 and 1.98. The Examiner is requested to review, consider and document each such item in the official record of this application.

04/27/2004 MBERHE

00000138 501698

10007204

01 FC:1806

180.00 DA

Note: If thi	s box is checked, this case was filed after June 30, 2003 and qualifies for
the blanket	waiver of deposit of copies of U.S. Patents and U.S. Patent Application
Publications	s in accordance with the written waiver of 37 CFR §1.98 (a)(2)(i) dated July
11, 2003. A	accordingly, such copies are not attached.
·	
This Inform	nation Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98 is not to be
construed as	s a representation that a search has been made, that additional information
material to t	the examination of this application does not exist, or that any one or more of
these items	constitutes prior art.
	I ·
This statem	ent is filed pursuant to (CHECK ONE BOX):
	37 C.F.R. § 1.97(b). This information disclosure statement is filed either: (1) within three months of the filing date of a national application other than a continued prosecution application under §1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; (3) before the mailing date of a first office action on the merits; or (4) before the mailing of a first office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114, whichever event occurs last.
	Accordingly, this information disclosure statement requires no fee and no certification.
K	37 C.F.R. § 1.97(c). This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of any of the following: (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application.
	Accordingly, this information disclosure statement requires either: (1) the fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c); or (2) a certification according to 37 C.F.R. § 1.97 (e)(1) or (2).
	37 C.F.R. § 1.97(d). This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97 (c).

Accordingly, this information disclosure statement requires:

- (1) a certification in accordance with 37 C.F.R. § 1.97(e); and
- (2) the fee specified in 37 C.F.R. § 1.17 (p) to consider an information disclosure statement under 37 C.F.R. § 1.97(d).

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II

Fees Due (C	CHECK ONE BOX):
\boxtimes	No fee is due.
	The fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) or 37 C.F.R. § 1.97(d) is enclosed (\$180).
	·
Certification	(CHECK ONE BOX):
\boxtimes	No certification is necessary.
	Pursuant to 37 C.F.R. § 1.97(e)(1), the undersigned hereby certifies: That each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
	Pursuant to 37 C.F.R. § 1.97(e)(2), the undersigned hereby certifies: No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this information disclosure statement.

Docket No. 034298-124

IV

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the

Please charge any additional required fee or credit any overpayment to our deposit

validity of the application or any patent issued thereon.

Respectfully submitted,

THELEN REID & PRIEST LLP

Dated: April 73, 2004

account number 50-1698.

Adrienne Yeung

Reg. No. 44,000

THELEN REID & PRIEST LLP P.O. Box 640640 San Jose, CA 95164-0640 (408) 292-5800 direct dial (408) 287-8040 direct fax

Form PTO 1449 Atty. Docket No. Serial No. 034298-124 10/007/204 U.S. Department of Commerce (Rev. 2-32) Patent and Trademark Office Applicant: Mark Ashby Information Disclosure Statement by Applicant Filed: 11/8/01 Group: 3762 (Use several sheets if necessary) **U.S. Patent Documents** Class Subclass Date Init. Document No. Date Name Olsen 7/80 4,211,323 Α В 4,218,155 Weidner 8/80 Pawelchak 10/91 $\overline{\mathsf{c}}$ 4,292,972 12/88 D 4,238,480 Sawyer 4/82 4,323,072 Rosenbluth et al E 7/82 F 4,340,066 Shah 9/83 G 4,404,970 Sawyer 8/95 Н 5,437,292 Kipshidze Lee 8/95 I 5,443,481 2/96 J 5,490,736 Haber 6/96 K Krajicek 5,522,840 6/96 Clement L 5,527,332 5,676,689 Kensey 10/97 M 3/83 Thomas C. Krol N 4,573,576 11/24E/87 O 4,708,718 Daniels TON TON TON 9/89 P 4,869,143 Merrick 09/07/93 Klaveness Q 5,242,683 Kensey et al. 2/94 R 5,282,827 4/96 S 5,507,279 Fortune Illi 02/11/97 T 5,601,603 07/21/98 U 5,782,861 Cragg, et al. 02/09/99 $\overline{\mathsf{v}}$ 5,868,762 Cragg, et al. 5/99 W 5,902,310 Foerster et al. Cragg, et al. 11/16/99 X 5,984,950 12/28/99 Nash, et al. Y 6,007,563 06/06/00 Z 6,071,300 Brenneman, et al. Cragg et al. 12/00 A1 6,162,192 03/13/01 B1 6,200,328 Cragg, et al. 4/11/02 C1 US2002/0042378 Reich et al D1 US2003/0088271 Cragg et al 5/8/03 Date Considered Examiner

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

We Se July 3 Atty. Docket No. Serial No. Form PTO 1449 034298-124 10/007/204 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office Applicant: Mark Ashby Information Disclosure Statement by Applicant Filed: 11/8/01 Group: 3762 (Use several sheets if necessary) **U.S. Patent Documents** Document No. Class Subclass Date Date Name Init. Εī 3,358,689 John L. Higgins 12/19/67 F1 3,411,505 P.D. Nobis 11/19/68 6/5/73 G1 3,736,939 Glenn N. Taylor 7/4/78 Solomon Rosenblatt H1 4,098,728 8/26/80 Terry No. Layton **I**1 4,219,026 9/30/80 Jonathan Cohen J1 4,224,945 9/20/83 Constantin Copi K1 4,405,314 L1 4,699,616 George M. Norwak 10/13/87 Sagae, et al 5/23/89 M1 4,832,688 Yoshino 6/13/89 N1 4,839,204 9/17/91 Chevalier et al 01 5,049,138 John L. Hahn 7/14/92 P1 5,129,889 3/9/93 Said Hilgal Q1 5,192,290 6/15/93 S1 5,219,899 Panster et al 8/3/93 <u>T1</u> Plass et al 5,232,453 John Haaga 10/19/93 U1 5,254,105 James Rudnick 6/14/94 $\overline{V1}$ 5,320,639 8/30/94 W1 Sonia Toller 5,342,388 9/27/94 5,350,399 Erlebacher et al X1 10/4/94 $\overline{Y1}$ 5,352,211 William Merskelly 9/5/95 Z15,447,502 John Haaga 10/17/95 A2 5,458,570 James May, Jr 8/13/96 B2 Abidin et al 5,545,175 Connie Toro 11/5/96 C2 5,571,168 Tal et al 2/11/97 D2 5,601,601 4/15/97 Wouter M. Muijs Van De E2 5,620,461 Nikhil K. Kundel 10/7/97 F2 5,674,346 G2 5,707,393 Kensey et al 1/13/98 8/3/99 H2 5,931,165 Reich et al Date Considered Examiner

30 5

Atty. Docket No. Serial No. 10/007/204 U.S. Department of Commerce 034298-124 Patent and Trademark Office Applicant: Mark Ashby Information Disclosure Statement by Applicant Filed: 11/8/01 Group: 3762 APR 2 6 2004 (Use several sheets if necessary) **U.S. Patent Documents** Document No. Date Class Subclass Date Name 2,370,319 J.G. Lippincott 2/45 J2 2,874,776 H.E. Hooe 2/59 Seaman et al K2 4,644,649 2/87 3/95 L2 5,399,361 Song, et al 5,462,194 Keith Barawell 10/95 M2 Benjamin Lee 3/7/00 N2 6,033,427 Cates et al 5/2/00 O2 6,056,768 Wallace et al 5/23/00 P2 6,066,325 O2 6.090,130 Nash et al 7/18/00 R2 Shchervinsky et al 10/3/00 6,126,675 S2 6,371,974 Brenneman et al 4/02 6,440,151 8/02 <u>T2</u> Cragg et al 8/02 U2 6,440,153 Cragg et al 9/02 V2 Cragg et al 6,477,534 Julian Lo 1/03 W2 6,503,222 X2 6,527,734 Cragg et al 3/03 4/03 <u>Y2</u> 6,540,735 Ashby et al **Z**2 6,544,236 Cragg et al 4/03 8/03 6,610,026 A3 Cragg et al 4,836,204 A4 US2002/000289 Ashby et al 1/021 AA1 Ashby et al 2/02 BB1 US2002/0016612 Chi Sing et al 1/04 CC1 US2004/0019328 DD1 US2004/0019330 Mark Ashby 1/04 EE1 US2003/0028140 Richard J. Greff 2/03 3/02 FFI US2002/0038133 Chi Sing 5/02 EE1 US2002/0062104 Ashby et al US2003/0088269 Mark Ashby 5/03 GG1 HHI US2003/0120258 Ashby et al 6/03 Cragg et al 7/03 ΠI US2003/0135237 US2002/0156495 Brenneman et al 10/02 JJ1 Date Considered Examiner

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

SUB-Q 1449 FOREIGN

4075

Form PTO 1449
(Rev. 2-32)
U.S. Department of Commerce
Patent and Trademark Office

Inf rmation Disclosure Statement by Applicant

Filed: 11/8/01

Group: 3762

APR 2 6 2004

Foreign Documents

Init a TEA	OF THE REAL PROPERTY.							nslatio
Init.		Document No.	Date	Country	Class	Subclass	Yes	No
	B4/	0557963	02/93	EP				
	C4/	0637431	11/94	EP				
	D4	0637432	7/94	EP				
	E4 /	WO 91/12847	09/91	PCT				
	F4	WO 94/02072	2/94	PCT				
	G4 ~	WO 94/28800	12/94	PCT				
	H4/	WO 95/28124	10/95	PCT				
	I4 /	WO 95/32669	12/95	PCT				
	J5 🗸	WO 95/32671	12/95	PCT				
	K5	WO 95/32679	12/95	PCT				
	L5 ,	WO 96/08208	03/96	PCT				
	M5	WO 96/24290	08/96	PCT				
	N5	WO 97/09934	3/97	PCT	To the second	AFEC 8 1004 APR 1 8 1004 APR 1 GENTER 23700		
	O5 /	WO 98/06346	02/98	PCT	•	LPR 18 DOM		
•	P5 /	WO 99/66834	12/99	PCT		200	ł\	
			-			9 00		
						THE SE	M	
						THE P	C	
						337		
						9		
•	-							
•								
	 	.'						



SUB-Q 1449 OTHER/ARTICLES

Serial No. Atty. Docket No. Form PTO 1449 10/007/204 034298-124 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office Applicant: Mark Ashby Information Disclosure Statement by Applicant Group: 3762 Filed: 11/8/01 (Use several sheets if necessary) Berman, et al "Guided Direct Antegrade Puncture of the Superficial Femoral Artery" AJR 147:632-634, 9/86 Q5 0361-803X/86/1473-0632 © American Roentgen Ray Society Berman et al "Modification of the Cope Drainage Catheter to Facilitate Placement" AJR 146:169-170, 1/86 R5 0361-803X/86/1461-0169 © American Ray Society Bryne, J. Review Article: Endovascular treatments for intracranial aneurysms, 1996 The British journal of radiology; 98,891-899 Correll, John T., et al., A new Physiologically absorbable sponge Correll, John T. et al. Biologic investigations of new absorbable sponge; pg 585 V5 / Journal of interventional cardiology volume 5 no. 2 June Kassell, et al. Size of Intracanial aneurysm; vol. 12, no. 3, (1983) W5/ Scharader, R. "Collagen appl.," Catheterization & cardiovascular diagnosis (1992) pp. 298-302 X5 Schievink, et al. The New England Journal of Medicine; review articles; intracanial aneurysms; Jan. 2 1997 Y5. Saddekni, MD et al "Antegrade Catheterization of the Superficial Femoral Artery" Radiiology 1985 **Z**5 157:561-532 Szikora, et al. Combined Use of stents and cells to treat experimental wide-necked carotid aneurysms: **A6** Preliminary results; AJNR AM newradiol 15: 1091-1102, June 94 Szikora, et al. Endovascular treatment of experimental aneurysms with liquid polymers: vol. 38, no. 2, Feb. **B6** Turiman, et al. Combined stent implantation & endovascular coil placement for treatment of experimental C6 wide-necked aneurysms: AJNRAM J. Neuroradio 15: 1087-1090 June 94 Vogelzang "A Modified Cope Introducing Dilator to Allow Straight Guide Wire Introduction" AJR 146:381-D6~ 382 2/86 0361-803X/86/1462-0381 © American Roentgen Ray Society Yoshimoto, et al cerebral aneurysms unrelated to arterial bifurcations; Acta neurochir (Wien) (96) 138: 958-<u>E6</u> 964 TECHNOLOGY CENTER BOTTO